HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.

AbstractOBJECTIVES:
To compare the efficacy of a 4-week ofloxacin-containing regimen and the standard WHO-MDT regimen for PB leprosy, in terms of the rate and timing of relapse after treatment completion.
DESIGN:
124 PB patients were enrolled in a randomised, double-blind trial. Of these, 66 received the standard 6-month WHO-MDT regimen, whereas 58 received 28 daily supervised doses of rifampicin 600mg + ofloxacin 400 mg, plus 5 months of placebo. Patients were regularly monitored for clinical response and for signs of relapse after treatment completion.
RESULTS:
Patients enrolled in the ofloxacin group had a mean follow-up of 10.8 years (628 patient-years) with 1 early relapse at 3 years after treatment completion. On relapse, this patient remained smear negative but was reclassified by current WHO criteria (> or =6 skin lesions) as multibacillary (MB). Patients on the WHO-MDT regimen had a mean follow-up of 11.3 years (749 patient-years) with two late relapses at 8 and 12 years, both still classified as PB on relapse.
CONCLUSION:
In conclusion, both regimens appeared generally efficacious, and, in particular, resulted in few relapses.
AuthorsMarivic F Balagon, Roland V Cellona, Rodolfo M Abalos, Robert H Gelber, Paul R Saunderson
JournalLeprosy review (Lepr Rev) Vol. 81 Issue 1 Pg. 27-33 (Mar 2010) ISSN: 0305-7518 [Print] England
PMID20496567 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Leprostatic Agents
  • Dapsone
  • Ofloxacin
  • Rifampin
Topics
  • Adult
  • Dapsone (therapeutic use)
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Leprostatic Agents (therapeutic use)
  • Leprosy, Paucibacillary (drug therapy)
  • Male
  • Middle Aged
  • Ofloxacin (therapeutic use)
  • Recurrence
  • Rifampin (therapeutic use)
  • Skin (microbiology)
  • Time Factors
  • Treatment Outcome
  • World Health Organization

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: